Lipid nanoparticle manufacturing for mRNA therapeutics cannot scale beyond microfluidic chips without changing particle properties

The mRNA-LNP vaccines from Pfizer-BioNTech and Moderna proved that lipid nanoparticles work. But the manufacturing process that produces them — rapid mixing through microfluidic channels — was never designed for industrial scale. Microfluidic chips fabricated in cyclic olefin copolymer (COC) degrade after repeated use because LNP formulation components interact with the chip material. A single chip produces on the order of milliliters per minute. Scaling to the hundreds of liters per hour needed for global vaccine supply requires parallelizing hundreds of chips or switching to impinging jet mixers, but both approaches alter the mixing dynamics that determine particle size, polydispersity, and mRNA encapsulation efficiency. The real pain is that LNP properties are exquisitely sensitive to mixing conditions. Change the flow rate, the channel geometry, or the Reynolds number, and you change the particle. A 10 nm shift in mean diameter or a 5% drop in encapsulation efficiency can push a batch out of specification and into the reject pile. For companies developing mRNA therapeutics beyond COVID — cancer vaccines, rare disease treatments, gene editing delivery — this means that the formulation optimized at bench scale may not be the same formulation produced at clinical or commercial scale. Every scale-up is essentially a new development program. The problem persists because the physics of rapid nanoprecipitation fundamentally depends on mixing timescale relative to particle nucleation timescale. At bench scale, microfluidic channels achieve millisecond mixing. At production scale, maintaining that same mixing uniformity across a larger volume is a fluid dynamics problem that has no simple engineering solution. Companies like Precision NanoSystems (now Cytiva) have developed parallelized systems, and PNAS published a SCALAR platform achieving 17 L/h, but these remain expensive, proprietary, and not yet validated for the full range of LNP compositions needed for next-generation therapeutics.